Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease

Experimental Hematology

Volumn 38, Issue 2, 2010, Pages 141-153

  Todoerti, Katia ^a   Lisignoli, Gina ^b   Storti, Paola ^c   Agnelli, Luca ^a   Novara, Francesca ^d   Manferdini, Cristina ^b   Codeluppi, Katia ^b   Colla, Simona ^c   Crugnola, Monica ^c   Abeltino, Manuela ^c   Bolzoni, Marina ^c   Sgobba, Valentina ^c   Facchini, Andrea ^b   Lambertenghi Deliliers, Giorgio ^a   Zuffardi, Orsetta ^d   Rizzoli, Vittorio ^c   Neri, Antonino ^a   Giuliani, Nicola ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Laboratorio di Immunologia e Genetica   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN; AUTOANTIGEN; COMPLEMENT COMPONENT C1; CYCLIN E; DECORIN; DEOXYCYTIDINE KINASE; DICKKOPF 1 PROTEIN; GUANOSINE TRIPHOSPHATASE; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBIN; METHIONINE ADENOSYLTRANSFERASE; MINICHROMOSOME MAINTENANCE PROTEIN 4; MITOCHONDRIAL PROTEIN; NUCLEAR CAP BINDING PROTEIN; NUCLEOPORIN; OSTEOPROTEGERIN; OXIDOREDUCTASE; PHOSPHOPROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; STATHMIN; TRANSCRIPTION FACTOR RUNX2; ZINC FINGER PROTEIN;

ARTICLE; BONE BIOPSY; BONE DISEASE; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MESENCHYME CELL; MICROARRAY ANALYSIS; MICROENVIRONMENT; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

BONE AND BONES; BONE REMODELING; CELL DIVISION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MESENCHYMAL STEM CELLS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOLYSIS; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 74249093697     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.11.009     Document Type: Article

References (53)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Lentzsch S., Ehrlich L.A., and Roodman G.D. Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 21 (2007) 1035-1049
3. Bataille R., Chappard D., Marcelli C., et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7 (1989) 1909-1914
4. Giuliani N., Rizzoli V., and Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108 (2006) 3992-3996
5. Giuliani N., Colla S., Morandi F., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106 (2005) 2472-2483
6. Yaccoby S., Wezeman M.J., Zangari M., et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91 (2006) 192-199
7. Robbiani D.F., Chesi M., and Bergsagel P.L. Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 351 (2004) 197-198
8. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
9. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., and Shaughnessy Jr. J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (2007) 2106-2111
10. Corre J., Mahtouk K., Attal M., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21 (2007) 1079-1088
11. Garderet L., Mazurier C., Chapel A., et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 48 (2007) 2032-2041
12. Arnulf B., Lecourt S., Soulier J., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21 (2007) 158-163
13. Robey P.G., and Termine J.D. Human bone cells in vitro. Calcif Tissue Int 37 (1985) 453-460
14. Lisignoli G., Piacentini A., Toneguzzi S., et al. Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M. Clin Exp Immunol 119 (2000) 346-353
15. Giuliani N., Lisignoli G., Colla S., et al. CC-chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 68 (2008) 6840-6850
16. Mattioli M., Agnelli L., Fabris S., et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24 (2005) 2461-2473
17. Agnelli L., Bicciato S., Mattioli M., et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 23 (2005) 7296-7306
18. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98 (2001) 5116-5121
19. Schadt E.E., Li C., Su C., and Wong W.H. Analyzing high-density oligonucleotide gene expression array data. J Cell Biochem 80 (2000) 192-202
20. Giuliani N., Colla S., Morandi F., Barille-Nion S., and Rizzoli V. Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells. Haematologica 90 (2005) 275-278
21. Haaber J., Abildgaard N., Knudsen L.M., et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 140 (2008) 25-35
22. Magrangeas F., Nasser V., Avet-Loiseau H., et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101 (2003) 4998-5006
23. Edwards C.M., Zhuang J., and Mundy G.R. The pathogenesis of the bone disease of multiple myeloma. Bone 42 (2008) 1007-1013
24. Mitsiades C.S., McMillin D.W., Klippel S., et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 21 (2007) 1007-1034
25. Giuliani N., and Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma 48 (2007) 2323-2329
26. Roodman G.D. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80 Suppl (1997) 1557-1563
27. Wallace S.R., Oken M.M., Lunetta K.L., Panoskaltsis-Mortari A., and Masellis A.M. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 91 (2001) 1219-1230
28. Garayoa M., Garcia J.L., Santamaria C., et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23 (2009) 1515-1527
29. Tanabe S., Sato Y., Suzuki T., Suzuki K., Nagao T., and Yamaguchi T. Gene expression profiling of human mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture. J Biochem 144 (2008) 399-408
30. Schilling T., Küffner R., Klein-Hitpass L., Zimmer R., Jakob F., and Schütze N. Microarray analyses of transdifferentiated mesenchymal stem cells. J Cell Biochem 103 (2008) 413-433
31. Sakaguchi Y., Sekiya I., Yagishita K., Ichinose S., Shinomiya K., and Muneta T. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood 104 (2004) 2728-2735
32. Sanchez-Guijo F.M., Blanco J.F., Cruz G., et al. Multiparametric comparison of mesenchymal stromal cells obtained from trabecular bone by using a novel isolation method with those obtained by iliac crest aspiration from the same subjects. Cell Tissue Res 336 (2009) 501-507
33. Lisignoli G., Codeluppi K., Todoerti K., et al. Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix protein. J Cell Physiol 220 (2009) 401-409
34. Lisignoli G., Cristino S., Toneguzzi S., et al. IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp Gerontol 39 (2004) 659-665
35. Jilka R.L., Weinstein R.S., Parfitt A.M., and Manolagas S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22 (2007) 1492-1501
36. Gruber H.E., Ivey J.L., Thompson E.R., Chesnut III C.H., and Baylink D.J. Osteoblast and osteoclast cell number and cell activity in postmenopausal osteoporosis. Miner Electrolyte Metab 12 (1986) 246-254
37. Bataille R., Chappard D., Marcelli C., et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88 (1991) 62-66
38. Phinney D.G., Gray A.J., Hill K., and Pandey A. Murine mesenchymal and embryonic stem cells express a similar Hox gene profile. Biochem Biophys Res Commun 338 (2005) 1759-1765
39. Chung N., Jee B.K., Chae S.W., Jeon Y.W., Lee K.H., and Rha H.K. HOX gene analysis of endothelial cell differentiation in human bone marrow-derived mesenchymal stem cells. Mol Biol Rep 36 (2009) 227-235
40. Ria R., Piccoli C., Cirulli T., et al. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clin Cancer Res 14 (2008) 1678-1685
41. Vacca A., Ria R., Semeraro F., et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102 (2003) 3340-3348
42. Serria M.S., Ikeda H., Omoteyama K., Hirokawa J., Nishi S., and Sakai M. Regulation and differential expression of the c-maf gene in differentiating cultured cells. Biochem Biophys Res Commun 310 (2003) 318-326
43. MacLean H.E., Kim J.I., Glimcher M.J., Wang J., Kronenberg H.M., and Glimcher L.H. Absence of transcription factor c-maf causes abnormal terminal differentiation of hypertrophic chondrocytes during endochondral bone development. Dev Biol 262 (2003) 51-63
44. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
45. Aqeilan R.I., Hassan M.Q., de Bruin A., et al. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem 283 (2008) 21629-21639
46. Li X., Pennisi A., and Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 112 (2008) 159-168
47. Atkins G.J., Kostakis P., Pan B., et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 18 (2003) 1088-1098
48. Qiang Y.W., Shaughnessy Jr. J.D., and Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112 (2008) 374-382
49. Edwards C.M., Edwards J.R., Lwin S.T., et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111 (2008) 2833-2842
50. Li B., Shi M., Li J., et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev 16 (2007) 921-930
51. Franceschi R.T., and Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88 (2003) 446-454
52. Suh J.H., Lee H.W., Lee J.W., and Kim J.B. Hes1 stimulates transcriptional activity of Runx2 by increasing protein stabilization during osteoblast differentiation. Biochem Biophys Res Commun 367 (2008) 97-102
53. Li X., Huang M., Zheng H., et al. CHIP promotes Runx2 degradation and negatively regulates osteoblast differentiation. J Cell Biol 181 (2008) 959-972